Antihypertensives were used more frequently in CKD controls (each p < 0.01, Table 1), as were erythropoietin (25.9% CKD vs. 20.2% INC) and iron substitution (30.2% CKD vs. 21.3% INC), though not significantly. This evidence concerns the gene EPO and chronic kidney disease.